Novel Kv1.3 blockers for immunosuppression: WO2012155199

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.11, 2013-11, pp. : 1511-1516

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840

By Wulff Heike

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1759-1765

Informa Healthcare

Access to resources Recommend Favorite

Human T-cell Kv1.3 potassium channel blockers: new strategies for immunosuppression

By Lew A. Chamberlin A.R.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 6, 2000-06 ,pp. : 905-915

Informa Healthcare

Access to resources Recommend Favorite

Use of Kv1.3 Blockers for Inflammatory Skin Conditions

Current Medicinal Chemistry, Vol. 17, Iss. 26, 2010-09 ,pp. : 2882-2896

Bentham Science Publishers

Access to resources Recommend Favorite

K+ Channel Blockers: Novel Tools to Inhibit T Cell Activation Leading to Specific Immunosuppression

Current Pharmaceutical Design, Vol. 12, Iss. 18, 2006-06 ,pp. : 2199-2220

Bentham Science Publishers

Access to resources Recommend Favorite

Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias

By Brendel Joachim Peukert Stefan

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 11, 2002-11 ,pp. : 1589-1598

Informa Healthcare

Access to resources Recommend Favorite